Micosis fungoide tratada con bexaroteno. Estudio de 13 casos / Mycosis fungoid treated with oral bexarotene: Study of 13 cases

No disponible

Disqueratoma verrucoso. Revisión de nuestros casos / Warty diskeratoma. Review of our cases

El disqueratoma verrucoso (DV) es una lesión tumoral benigna poco frecuente que aparece entre la cuarta y la sexta década de la vida en áreas fotoexpuestas. Presentamos los únicos cinco casos de disqueratoma verrucoso acontecidos en nuestro centro en los últimos diecisiete años, detectados mediante un estudio descriptivo retrospectivo de todas las biopsias practicadas en nuestra área de salud. El DV representa un porcentaje del 0,1% del total de biopsias realizadas

Warty dyskeratoma (VD) is an infrequent benign tumor that appears on patients in the fourth to sixth decades on sun-exposed areas. We present the only five cases of warty dyskeratoma removed in our department since seventeen years ago, that they are detected by a retrospective descriptive study about all the biopsies realized on our sanitary area. DV represent a proportion of 0.1% of the realized biopsies

Familial necrobiosis lipoidica not associated with diabetes.

A 42-year-old woman presented with a 12-year history of extensive yellow and erythematous plaques, round and oblong with irregular configuration and glossy atrophic central areas on the pretibial aspects of both legs. Her 45-year-old sister presented with a 7-year history of a single plaque with erythematous margins, abundant telangiectases, and an atrophic center in the lower portion of the left leg. There was no family history of type-1 or type-2 diabetes mellitus. Both patients had normal fasting glucose concentration, oral glucose tolerance test, and glucose overload test. Different treatment options including topical corticosteroids were unsuccessful. Treatment with oral fumaric acid esters was attempted but the medication was discontinued because of intolerable side effects (flushing and gastrointestinal discomfort). At present, after a follow-up of 2 years, the plaques remain unchanged. These two cases should be added to the few cases of familial nondiabetic necrobiosis lipoidica previously reported.

Tratamiento de las micosis superficiales con eberconazol / Treatment in superficial cutaneous mycoses with eberconazole

El eberconazol es un compuesto imidazólico de aplicación tópica con actividad fungistática y fungicida a altas dosis, de amplio espectro de acción, caracterizado por poseer una estructura molecular de tipo hidrófilo-lipófilo que favorece la penetrabilidad y la permanencia en la piel. Los componentes galénicos de este azol tópico favorecen y optimizan la acción del fármaco en la piel. Los ésteres de ácidos grasos facilitan la penetración en la piel y la extensibilidad de la crema, mientras que las poliacrilamidas producen un efecto filmógeno y facilitan la permanencia del principio activo en la piel. Estudios preclínicos han mostrado una alto grado de actividad in vitro frente a especies de Candida, incluyendo C. tropicalis, dermatófitos y Malassezia furfur. En un estudio reciente, el eberconazol mostró una actividad in vitro superior al clotrimazol, el ketoconazol y el miconazol frente a 200 cepas de dermatófitos. El eberconazol ha mostrado actividad en pruebas in vivo: dermatofitosis, candidiasis y pitiriasis experimentales del cobayo. No presenta hipersensibilidad retardada, y no produce fotosensibilidad, efecto fototóxico ni absorción sistémica. Ha demostrado una eficacia superior que el clotrimazol en crema al 1% y equivalencia terapéutica con miconazol al 2% en el tratamiento de las micosis cutáneas producidas por dermatófitos, con una eficacia similar en el tratamiento de la candidiasis y la pitiriasis versicolor. Por todo ello, puede considerarse su uso en la práctica clínica habitual (AU)

Eberconazole is an imidazolic compound for topical application, with fungistatic and fungicidal activity at high doses, and a broad spectrum of action, characterized by a hydrophilic-lipophilic molecular structure favoring penetration and continuance in the skin. The galenic components of this topical azole favor and optimize the drug’s action in the skin, fatty acid esters facilitate penetration in the skin and make the cream easy to spread, while polyacrylamides produce an filmogenous effect and facilitate the continuance of the active principle in the skin. Preclinical studies have shown a high degree of activity in vitro against Candida spp., including Candida tropicalis, dermatophytes and Malassezia furfur. In a recent study, eberconazole showed an in vitro activity superior to that of clotrimazole, ketoconazole and miconazole against 200 strains of dermatophytes. Eberconazole has shown activity in in vitro tests: experimental dermatophytosis, candidiasis and dermatophytoses in guinea pigs. It does not produced delayed hypersensitivity, photosensitivity or phototoxic effects or systemic absorption. It has shown greater efficacy than clotrimazole 1% and therapeutic equivalence to miconazole 2% in the treatment of cutaneous mycoses produced by dermatophytes, and has similar efficacy in the treatment of candidiasis and pityriasis versicolor. In view of the above, eberconazole can be used in routine daily clinical practice (AU)